Nat Chem Biol 5:749757 Finan B, Clemmensen C, Muller TD (2015) Emerging opportunities for the treatment of metabolic diseases: glucagon-like peptide-1 based multi-agonists
If a patient suspects improper storagewhether due to a refrigerator malfunction, accidental freezing, or prolonged heat exposurethey should contact their healthcare provider, pharmacist, or the manufacturer (Novo Nordisk) before using the medication
We need to understand the whole picture
For all included trials, the risks for gallbladder or biliary diseases were higher with higher doses of GLP-1 RA use versus lower doses and for longer versus shorter duration of use
Such medications are occasionally tried on a case-by-case basis
Only the tips of the stigmas, particularly rich in active compounds, are carefully selected